69229-98-7

Upstream product

• 2835-77-0 (2-aminophenyl)(phenyl)methanone 
• 623-47-2 propynoic acid ethyl ester 
• 100-39-0 benzyl bromide 
• 622-79-7 benzyl azide 
• 2216-94-6 phenylpropynoic acid ethyl ester 
• 141-97-9 ethyl acetoacetate 
• 13720-94-0 ethyl 4-chloroquinoline-3-carboxylate 
• 98-80-6 phenylboronic acid 

Downstream Products

• 94191-61-4 1-(4-phenylquinolin-3-yl)ethan-1-one 
• 92795-26-1 4-phenyl-3-quinolinecarboxylic acid 

Relevant academic research and scientific papers

Regioselective intramolecular annulations of ambident β-enamino esters: A diversity-oriented synthesis of nitrogen-containing privileged molecules

Diversity-oriented, regioselective, intramolecular annulation of β-enamino esters is described under solvent-free, calcium-catalysis. 2-aminoaryl ketones and alkyl propiolates undergone a [4+2] annulation to yield substituted quinolines; with an excess of

HETEROARYL INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Copper promoted synthesis of substituted quinolines from benzylic azides and alkynes

A novel copper promoted synthesis of substituted quinolines from various benzylic azides and internal alkynes has been demonstrated. The reaction features a broad substrate scope, high product yields and excellent regioselectivity. In contrast to the known two-step process of acid promoted [4 + 2] cycloaddition reaction and oxidation, the present methodology allows the synthesis of quinolines in a single step under neutral reaction conditions and can be applied to the synthesis of biologically active 6-chloro-2,3-dimethyl-4-phenylquinoline (antiparasitic agent) and 3,4-diphenylquinolin-2(1H)-one (p38αMAP kinase inhibitor). A plausible reaction mechanism involves rearrangement of benzylic azide to N-arylimine (Schmidt reaction) followed by intermolecular [4 + 2] cycloaddition with internal alkynes.

Investigation of prototypal MOFs consisting of polyhedral cages with accessible Lewis-acid sites for quinoline synthesis

A series of prototypal metal-organic frameworks (MOFs) consisting of polyhedral cages with accessible Lewis-acid sites, have been systematically investigated for Friedl?nder annulation reaction, a straightforward approach to synthesizing quinoline and its derivatives. Amongst them MMCF-2 demonstrates significantly enhanced catalytic activity compared with the benchmark MOFs, HKUST-1 and MOF-505, as a result of a high-density of accessible Cu(II) Lewis acid sites and large window size in the cuboctahedral cage-based nanoreactor of MMCF-2.

Cu2+-doped zeolitic imidazolate frameworks (ZIF-8): Efficient and stable catalysts for cycloadditions and condensation reactions

Cu2+-doped zeolitic imidazolate framework (ZIF) crystals were efficiently prepared by reaction of Cu(NO3)2, Zn(NO3)2, and 2-methylimidazole in methanol at room temperature. Scanning electron microscopy, transmission electron microscopy and X-ray diffraction showed that the Cu/ZIF-8 particles were nanosized (between ca. 120 and 170 nm) and that the body-centered cubic crystal lattice of the parent ZIF-8 framework is continuously maintained, regardless of the doping percentage. Moreover, thermogravimetric analyses and specific BET surface area measurements demonstrated that the doping does not alter the high stability of ZIF-8 crystals and that the porosity only decreases at a high doping percentage (25% in Cu2+). The Cu/ZIF-8 material showed excellent catalytic activity in the [3 + 2] cycloaddition of organic azides with alkynes and in Friedl?nder and Combes condensations due to the high catalyst surface area and the high dispersion of Cu/ZIF-8 particles. Notably, the Cu/ZIF-8 particles not only exhibit excellent performance but also show great stability in the reaction, allowing their reuse up to ten times in condensation reactions. Our findings explored a simple and powerful way to incorporate metal ions into the backbones of open framework materials without losing their properties.

5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention aLso enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo- dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.